Expertise in
2
conditions

Dr. Marie-louise C. Vachon

Hepatology
Office
5 E 98th St Fl 11, 
New York, NY 
Expertise in
2
conditions
Office
5 E 98th St Fl 11, 
New York, NY 

Overview

Marie-louise Vachon is a Hepatologist practicing medicine in New York, New York.

Dr. Vachon is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Hepatitis C, Hepatitis, Cirrhosis, and Portal Hypertension.

She is actively involved in clinical research, co-authoring 27 peer reviewed articles and participating in 8 clinical trials.

Specialties

Hepatology

Licenses

Internal Medicine in NY

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
5 E 98th St Fl 11, New York, NY 10029

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
Enrollment Status: Terminated
Publish Date: April 20, 2025
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Enrollment Status: Terminated
Publish Date: February 20, 2025
Intervention Type: Biological, Drug
Study Drug: RSV Maternal vaccine
Study Phase: Phase 3
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Combination product, Biological
Study Phase: Phase 3
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
Enrollment Status: Terminated
Publish Date: December 14, 2023
Intervention Type: Drug
Study Drugs: GSK3640254, Dolutegravir, Lamivudine
Study Phase: Phase 2
CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection
CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Enrollment Status: Completed
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers
A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers
Enrollment Status: Completed
Publish Date: December 13, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Enrollment Status: Completed
Publish Date: December 11, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

27 Total Publications

SARS-CoV-2 Infection and COVID-19 Vaccine Antibody Responses in Two Canadian Cohorts of Persons Living with HIV.
SARS-CoV-2 Infection and COVID-19 Vaccine Antibody Responses in Two Canadian Cohorts of Persons Living with HIV.
Journal: Antibodies (Basel, Switzerland)
Published: February 26, 2026
Similar Doctors
Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

RMTI Liver Disease - Summit Health

1 Diamond Hill Rd Fl 4, 
Berkeley Heights, NJ 
 (26.4 miles away)
212-257-0031
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Odin is a Hepatologist practicing medicine in Berkeley Heights, New Jersey. Dr. Odin is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Primary Biliary Cholangitis, Cholangitis, Hepatitis, Endoscopy, and Liver Transplant.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
 (2.7 miles away)
929-343-3573
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Maya Gambarin-Gelwan is a Hepatologist practicing medicine in New York, New York. Dr. Gambarin-Gelwan is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Visceromegaly, Non-Alcoholic Fatty Liver Disease, Enlarged Liver, Endoscopy, and Liver Embolization.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

Rutgers Health Hepatology

140 Bergen St # D-1650, 
Newark, NJ 
 (13.5 miles away)
732-908-1551
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mumtaz Niazi is a Hepatologist practicing medicine in Newark, New Jersey. Dr. Niazi is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Hepatitis, Visceromegaly, Alcoholic Cirrhosis, Liver Transplant, and Endoscopy. Dr. Niazi is currently accepting new patients.

Frequently Asked Questions about Dr. Marie-louise C. Vachon

How do I make an appointment with Dr. Marie-louise C. Vachon?

You can book an appointment with Dr. Marie-louise C. Vachon by calling their office at 212-241-7270. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Marie-louise C. Vachon a top-rated expert for Hepatitis C?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Marie-louise C. Vachon is classified as an Advanced expert for Hepatitis C, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Marie-louise C. Vachon specialize in?

While Dr. Marie-louise C. Vachon is a Hepatology, they have specific expertise in Hepatitis C, Hepatitis, and Cirrhosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hepatology.

Does Dr. Marie-louise C. Vachon participate in research or clinical trials?

Yes. Dr. Marie-louise C. Vachon has published 27 articles and abstracts on conditions like Hepatitis C. You can view a list of Dr. Marie-louise C. Vachon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vachon's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile